Compare CODA & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CODA | IMUX |
|---|---|---|
| Founded | 1994 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.4M | 152.6M |
| IPO Year | 2007 | 2013 |
| Metric | CODA | IMUX |
|---|---|---|
| Price | $11.66 | $12.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 126.8K | ★ 1.8M |
| Earning Date | 06-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.62 | ★ 38.00 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $20,316,161.00 | N/A |
| Revenue This Year | $18.28 | N/A |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | $148.19 | ★ N/A |
| Revenue Growth | ★ 4.98 | N/A |
| 52 Week Low | $5.98 | $0.51 |
| 52 Week High | $18.00 | $12.25 |
| Indicator | CODA | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 86.59 |
| Support Level | $10.81 | $0.75 |
| Resistance Level | $12.22 | N/A |
| Average True Range (ATR) | 0.51 | 1.03 |
| MACD | 0.05 | 0.36 |
| Stochastic Oscillator | 51.68 | 97.66 |
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.